Table 1.
Derived characteristics of malignant pleural mesothelioma (MPM) patients and patient-derived xenografts (PDXs).
| Patient | PDX | |||
|---|---|---|---|---|
| ID | Histology | Positive Marker | Histology | Positive Marker |
| MESO 3 | sarcomatoid | Vimentin, Cytokeratins AE1 and AE3 | sarcomatoid | Vimentin, Calretinin, Ki67 = 60% |
| MESO 4 | biphasic | Calretinin, Vimentin and WT1 (focal) | biphasic | Vimentin, Calretinin, Ki67 = 70% |
| MESO 7 | sarcomatoid | Vimentin, Cytokeratins AE1 and AE3 and WT1 (focal) | sarcomatoid | Vimentin, Calretinin, Ki67 = 60% |
| MESO 15 | epithelioid | Calretinin, WT1 (focal) and Vimentin | epithelioid | Vimentin, Calretinin, Ki67 = 40% |